Table 2.
Baseline Demographic and Clinical Characteristics of Randomized Patients a
| Characteristics | Combined treatment (n=633) |
Medication treatment (n=635) |
|---|---|---|
| Demographic | ||
| Age, y | 26.1(25.5–26.8) | 26.4(25.7–27.0) |
| Male No.(%) | 344 (54.3) | 354 (55.7) |
| Marital status No.(%) | ||
| Married | 167 (26.4) | 173 (27.2) |
| Previously married b | 39 (6.2) | 28 (4.4) |
| Never married | 427 (67.5) | 434 (68.3) |
| Education, y | 12.2(11.9–12.5) | 12.0(11.7–12.3) |
| Clinical | ||
| DSM-IV diagnosis No.(%) | ||
| Schizophrenia | 535(84.5) | 538(84.7) |
| Schizophreniform disorder | 98(15.5) | 97(15.3) |
| PANSS total score | 44.7(43.7–45.7) | 45.6(44.5–46.7) |
| CGI severity score | 2.5(2.4–2.6) | 2.6(2.5–2.7) |
| Age at onset, y | 23.8(23.2–24.4) | 24.2(23.4–24.6) |
| Duration of schizophrenia, mo | 24.6(23.0–26.3) | 23.3(21.7–24.9) |
| Daily dose of antipsychotic agents, mg/total No. | ||
| Chlorpromazine | 332.1(305.0–359.2)/95 | 344.9(319.0–370.8)/94 |
| Sulpiride | 720.3(673.2–767.4)/98 | 732.8(683.2–782.4)/97 |
| Clozapine | 267.0(244.0–290.0)/99 | 269.9(246.7–293.1)/99 |
| Risperidone | 3.5(3.3–3.7)/111 | 3.7(3.4–3.9)/112 |
| Olanzpine | 11.9(10.9–12.9)/79 | 12.4(11.1–13.7)/80 |
| Quetiapine | 538.2(490.2–586.2)/80 | 524.5(467.3–581.7)/81 |
| Aripiprazole | 18.5(16.9–20.1)/71 | 18.5(16.6–20.4)/72 |
Abbreviation: PANSS, the Positive and Negative Syndrome Scale; CGI, Clinical Global Impressions; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition
a
Data are presented as mean (95% confidence interval) unless otherwise indicated. Percentages may not sum to 100 due to rounding.
b
This category includes patients who were widowed, divorced, or separated.